MAX REINHARDT - 06 Jun 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
President, Rest of World
Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
06 Jun 2022
Net transactions value
-$323,737
Form type
4
Filing time
08 Jun 2022, 19:40:44 UTC
Previous filing
25 Apr 2022
Next filing
11 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Sale $172,891 -2,817 -9.5% $61.37 26,833 06 Jun 2022 Direct F1
transaction PCRX Common Stock Sale $150,846 -2,433 -9.1% $62.00 24,400 07 Jun 2022 Direct F2
transaction PCRX Common Stock Award $0 +7,950 +33% $0.000000 32,250 08 Jun 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Award $0 +19,900 $0.000000 19,900 08 Jun 2022 Common Stock 19,900 $59.39 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F3 Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F4 The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.